Basilea Pharmaceutica Ltd., a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, announced today that its license partner, Pfizer Inc., has received a Drug Approval License from the National Medical Products Administration (NMPA) in China, for the oral formulation of its antifungal Cresemba® (isavuconazole) for the treatment of adult patients with invasive aspergillosis.
Source:- Basilea Pharmaceutica Ltd.
According to a literature survey, Invasive Aspergillosis (IA) affects about 15,000 to 20,000 annually in the USA. t the incidence of IA is 5 to 25% in patients with acute leukemia, 5 to 10% in patients with allogeneic bone marrow transplantation, and 0.5 to 5% in patients with cytotoxic treatment of hematological diseases, autologous bone marrow transplantation, and solid organ transplantation (SOT). Among organ recipients, the incidence is highest in heart and lung transplant patients (19 to 26%) followed by liver, pancreas, and kidney transplants (1 to 10%)
Comprehensive insight on patient segmentation based on age, sex, Infection based on Aspergillus species; Aspergillus fumigatus, Aspergillus flavus, Aspergillus niger, Aspergillus sp, Classification based on comorbidity; Chemotherapy, Hypertension, Diabetes mellitus, Leukemia, Neutropenia, organ transplantation (Heart, Lungs, Liver, Kidney), COPD, CKD, Tuberculosis, Autoimmune disease, CAD, PH, Asthma, Cirrhosis, Cystic fibrosis, HIV, HSCT, COVID and Others, Site of Infection; Lung, Paranasal sinuses, Mediastinum, Peritoneum, Skin and Others, Hospitalization; ICU/ General ward, Symptoms, has been provided into the epidemiology section of the Invasive Aspergillosis (IA) and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China
In terms of pharmacologic therapies, there are many drug candidates are in different Phase (Phase I, II & III) stages of development. Key companies are, Merck Sharp & Dohme Corp., Pfizer/ Vicuron Pharmaceuticals, Astellas Pharma Global Development, Inc., F2G Biotech GmbH, Gilead Sciences, Basilea Pharmaceutica International Ltd, Nexstar Pharmaceuticals, Scynexis, Inc. are targeting the Invasive Aspergillosis (IA) market. Looking at the current clinical development and assets progress card, it would really be a great opportunity for the pharmaceutical company to build products around the treatment of Invasive Aspergillosis (IA) specifically for moderate to severe patients.
About Thelansis:
Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.
Other Reports:-
Acute Radiation Syndrome (ARS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030
Contact details:-
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India
Contact no.: +91(124) 404-1731
Sales office
183-Asylum Street Hartford, CT-06103, USA
USA +1 (267) 244-6955,
clientsupport@thelansis.com
m.berg@thelansis.com
Contact Information:
m.berg@thelansis.com
Tags:
Reportedtimes, PR-Wirein, iCN Internal Distribution, Research Newswire, English